The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - ASCO; Dana Farber Cancer Hospital; KidneyCan; NCCN
Stock and Other Ownership Interests - Pionyr; Tempest Therapeutics
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); Gateway for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Todd Michael Bauer
Employment - Tennessee Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Exelixis; Foundation Medicine; Guardant Health; Ignyta (Inst); Loxo; Moderna Therapeutics (Inst); Pfizer; Pfizer (Inst)
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Lilly
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Peleton (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Principa Biopharma (Inst); Roche (Inst); Sanofi (Inst); Stemline Therapeutics (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Pfizer; Pharmacyclics; Sysmex
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
Edward Arrowsmith
Employment - Tennessee Oncology
Stock and Other Ownership Interests - OneOncology
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calistoga Pharmaceuticals (Inst); Celgene (Inst); Cephalon (Inst); Chorus (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Eisai (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncogenex (Inst); Onyx (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Sarah Cannon Research Institute (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Flatiron Health; OneOncology; Sarah Cannon Research Institute
Other Relationship - Sarah Cannon Research Institute
 
Ananya Roy
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Donna Vickery
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck
Travel, Accommodations, Expenses - Merck
 
Scott S. Tykodi
Consulting or Advisory Role - Bristol-Myers Squibb; Intellisphere, LLC; Merck; Natera
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clinigen Group (Inst); Exelixis (Inst); Genentech (Inst); Jounce Therapeutics (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending (Inst)